The use of long noncoding RNA-lnc-TSI
Through the detection and expression regulation of long-chain non-coding RNA-lnc-TSI, the diagnosis and treatment problems of calcified aortic valve disease are solved, and new detection products and prevention and treatment plans are provided, reducing disease progression and treatment costs.
Patent Information
- Application Number
- CN202210417381.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-04-20
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2042-04-20
AI Technical Summary
Calcified aortic valve disease lacks effective prevention and treatment methods. The existing valve replacements have problems such as lifelong anticoagulation of mechanical valves and prone to calcification and decay of biological valves, resulting in huge social and economic burdens.
Develop long-chain non-coding RNA-lnc-TSI detectors and expression promoters for detection and regulation of calcification processes in aortic valve disease, as diagnostic markers and therapeutic targets, inhibiting osteogenic differentiation and alkalinity of VICs Phosphatase activity.
New aortic valve disease detection products and prevention and treatment programs are provided to reduce the progress of calcified aortic valve disease by inhibiting the expression of RUNx2 and college I, reducing surgical risks and treatment costs.
Smart Images

Figure CN114959008B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biotechnology, and in particular relates to the use of long non-coding RNA-lnc-TSI. Background Art
[0002] Calcific aortic valve disease (CAVD) is a group of diseases in which the aortic valve thickens and calcifies, eventually leading to severe stenosis of the valve orifice. It has become the most common valvular heart disease in high-income countries. Currently, there is no effective means to prevent CAVD. The treatment is mainly surgical or interventional valve replacement. However, surgery is risky and expensive, and existing valve substitutes have their own defects. Mechanical valves require lifelong anticoagulation and are prone to bleeding and embolism. Bioprosthetic valves are prone to calcification and decay, which can cause death and disability, causing huge social and economic burdens. Therefore, in-depth research on the pathogenesis of aortic valve calcification and finding effective drug intervention targets are of great clinical value and social significance.
[0003] The normal aortic valve leaflet tissue structure is divided into three layers, namely the fibrous layer (fibrosa) facing the aortic sinus, the ventricular layer (ventricularis) facing the ventricular surface, and the spongiosa (spongiosa) between the two. Valve interstitial cells (VICs) are distributed in each layer of tissue and are the most important cell type in the aortic valve, with a myofibroblast phenotype. Under the influence of pathological factors such as endothelial dysfunction, lipid deposition, inflammatory response, abnormal hemodynamics, TGF-β, and IL-6, VICs are activated and express osteogenic transcription factors such as Runx2 and SOX9, causing VICs to transdifferentiate into osteoblast-like cells, synthesizing increased bone matrix proteins and collagen, as well as calcium deposition-related alkaline phosphatase (ALP), etc., resulting in the local deposition of calcium hydroxyphosphate in the valve, which ultimately promotes calcification of the valve leaflet. Therefore, the phenotypic transformation of VICs plays a key role in the pathological process of CAVD.
[0004] Long noncoding RNA (lncRNA) refers to RNA molecules with transcript lengths between 200-100000nt. They do not encode proteins, are located in the nucleus or cytoplasm, and have a conserved secondary structure. Literature has reported that LncRNAMALAT1 aggravates aortic valve calcification by recruiting miR-195. DNA methylation changes in long noncoding RNAH19 promote aortic valve calcification by silencing NOTCH1. LncRNA OIP5-AS1 inhibits osteoblast differentiation of valvular interstitial cells through the miR-137 / TWIST11 axis. A large number of studies have shown that long noncoding RNA plays an important role in valvular calcification diseases. The above characteristics make long noncoding RNA have a very broad prospect for the development and application of new disease diagnosis and treatment methods. Summary of the invention
[0005] In view of the above problems, the present invention provides the use of long non-coding RNA-lnc-TSI, mainly to solve the regulatory application of long non-coding RNA-lnc-TSI in aortic valve disease, etc.
[0006] The present invention provides the following solutions:
[0007] Application of long noncoding RNA-lnc-TSI detection agent in the preparation of aortic valve disease detection products.
[0008] In some instances, the aortic valve disease comprises calcific aortic valve disease.
[0009] Application of long non-coding RNA-lnc-TSI detection agent in the preparation of aortic valve interstitial cell differentiation level detection products.
[0010] Application of long noncoding RNA-lnc-TSI as a molecular marker in the preparation of calcific aortic valvular disease detection model.
[0011] In some cases, the long noncoding RNA-lnc-TSI detector is an expression level detector.
[0012] In some cases, the long non-coding RNA-lnc-TSI detection agent is at least a detection primer (pair) and / or a detection probe; the aortic valve disease detection product is at least a kit containing a detection primer and / or a detection probe.
[0013] Application of a long non-coding RNA-lnc-TSI expression promoter or overexpressed long non-coding RNA-lnc-TSI in the preparation of an aortic valve interstitial cell activity inhibitor.
[0014] Application of a long non-coding RNA-lnc-TSI expression promoter or overexpressed long non-coding RNA-lnc-TSI in the preparation of an alkaline phosphatase activity inhibitor.
[0015] Use of a long non-coding RNA-lnc-TSI expression promoter or overexpression of long non-coding RNA-lnc-TSI in the preparation of a drug for treating aortic valve disease.
[0016] Application of a long non-coding RNA-lnc-TSI expression promoter or over-expressed long non-coding RNA-lnc-TSI in the preparation of drugs for diseases induced by elevated runx2 and collage I expression.
[0017] Application of a long non-coding RNA-lnc-TSI overexpression promoter or an overexpressed long non-coding RNA-lnc-TSI in preparing a runx2, collage I expression inhibitor or treating a runx2, collage I overexpression-induced disease.
[0018] The beneficial effects of the present invention are:
[0019] A new aortic valve disease detection product is provided. A prevention and treatment plan for aortic valve disease is also given. At the same time, corresponding regulation methods are also given for the regulation of the activity of some proteins, and plans are given for the preparation of some activity regulation products, including regulatory preparations for therapeutic purposes and non-therapeutic purposes. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 Bioinformatics analysis chart related to aortic valve disease;
[0021] Figure 2 VICs are activated in aortic valve disease, leading to high expression of RUNx2 and collageI;
[0022] Figure 3 VICs activation in aortic valve disease is accompanied by high expression of lnc-TSI;
[0023] Figure 4 Overexpression of lnc-TSIlnc-TSI alleviates osteogenic differentiation of VICs;
[0024] Figure 5 This is a diagram of the well plate solution state in the BCA method. DETAILED DESCRIPTION
[0025] The present invention will be further described below:
[0026] The first part introduces the use of long noncoding RNA-lnc-TSI as a marker for aortic valve disease detection :
[0027] First, the application of long non-coding RNA-lnc-TSI detection agent in the preparation of aortic valve disease detection products.
[0028] The long-chain non-coding RNA-lnc-TSI detection agent is a product for detecting long-chain non-coding RNA-lnc-TSI.
[0029] In some cases, the aortic valve disease includes calcific aortic valve disease. The expression level of long-chain non-coding RNA-lnc-TSI in the corresponding body is detected by a long-chain non-coding RNA-lnc-TSI detection agent, which plays a role in indexing the diagnosis of aortic valve disease. The expression level detection result is compared with the normal value. If the expression amount is increased, it is positively correlated with aortic valve disease.
[0030] Or, the application of long non-coding RNA-lnc-TSI as a molecular marker in the preparation of a calcific aortic valvular disease detection model. The calcific aortic valvular disease detection model is a disease prediction and analysis model.
[0031] Secondly, the application of long non-coding RNA-lnc-TSI detection agent in the preparation of aortic valve interstitial cell differentiation level detection products.
[0032] In the above two aspects, the long non-coding RNA-lnc-TSI detector is an expression level detector.
[0033] In the above, the long non-coding RNA-lnc-TSI detection agent is at least a detection primer (pair) and / or a detection probe; the aortic valve disease detection product is at least a kit containing a detection primer and / or a detection probe.
[0034] For example, a test kit includes a detection probe, a primer, and other necessary auxiliary agents (such as an enzyme), etc. Of course, other hybrid devices in use, as long as they include probes, primers, test kits, or are expected to be similar, should all be within the scope of the present invention.
[0035] The sequence of the detection primer pair is:
[0036] F:5'-AATCTGGTGTGGACAAACGC-3',
[0037] R:5'-AACAGATGCTTCCGAATGCC-3';
[0038] The sequence of the detection probe is: 5'-ACATCTCTTAATCAGCGAATCA-3'.
[0039] The second part introduces long noncoding RNA-lnc-TSI and its expression regulators as a drug for the prevention and treatment of aortic valve disease The use of things :
[0040] In the first aspect, the use of a long non-coding RNA-lnc-TSI expression promoter or an over-expressed long non-coding RNA-lnc-TSI in the preparation of an inhibitor of aortic valve interstitial cell activity. When the two are used in combination, it is also within the scope of the present invention.
[0041] Ultimately, the overexpression of long non-coding RNA-lnc-TSI inhibits the activity of aortic valve interstitial cells, which is mainly manifested in the regulation of cells. For example, inhibiting the osteoblastic differentiation of aortic valve interstitial cells is a manifestation of aortic valve interstitial cell activity.
[0042] Osteogenic differentiation of aortic valve interstitial cells also leads to increased expression of RUNx2 and collageI.
[0043] Among them, the expression promoter promotes the expression of long non-coding RNA-lnc-TSI, and its purpose is to increase the expression level of long non-coding RNA-lnc-TSI to the point where it can inhibit the activity of aortic valve interstitial cells. Of course, overexpression in clinical practice is one of the expression states, and overexpression has a corresponding cell inhibitory effect.
[0044] In the second aspect, the use of a long non-coding RNA-lnc-TSI expression promoter or an over-expressed long non-coding RNA-lnc-TSI in the preparation of a drug for treating aortic valve disease. When the two are used in combination, it is also within the scope of the present invention.
[0045] Ultimately, the overexpression of long noncoding RNA-lnc-TSI plays a preventive and therapeutic role in calcific aortic valve disease, which is mainly manifested by the regulatory effect on cells.
[0046] Among them, the expression promoter promotes the expression of long non-coding RNA-lnc-TSI, and its purpose is to increase the expression level of long non-coding RNA-lnc-TSI to the point where it can inhibit calcific aortic valve disease. Of course, overexpression in clinical practice is one of the expression states, and overexpression has an inhibitory effect on calcific aortic valve disease.
[0047] In the third aspect, the use of long non-coding RNA-lnc-TSI expression promoter or over-expressed long non-coding RNA-lnc-TSI in the preparation of runx2, collage I expression inhibitor. One manifestation is the use of drugs for treating diseases induced by high expression of runx2, collage I.
[0048] Similarly, the expression promoter promotes the expression of long non-coding RNA-lnc-TSI. Its purpose is to increase the expression level of long non-coding RNA-lnc-TSI to the point where it can inhibit the expression of runx2 and collage I. Of course, overexpression in clinical practice is one of the expression states. When overexpressed, it has a corresponding protein expression effect and achieves the treatment of corresponding diseases, such as vascular calcification. For example, the article on the relationship between runx2 and vascular calcification in the "Journal of Clinical Research, November 18, 2021" verified that inhibiting runx2 can prevent and treat vascular calcification.
[0049] In addition, it can also be used as a runx2, collage I expression inhibitor for non-diagnostic and therapeutic purposes, and can achieve corresponding regulatory effects in vitro. Long-chain non-coding RNA-lnc-TSI expression promoter or overexpressed long-chain non-coding RNA-lnc-TS in vitro experiments also show corresponding inhibitory effects, which can directly regulate the corresponding proteins. When it is an in vitro inhibitory preparation, the long-chain non-coding RNA-lnc-TSI expression promoter or overexpressed long-chain non-coding RNA-lnc-TSI is used in in vitro runx2, collageI expression inhibitors for non-diagnostic and therapeutic purposes.
[0050] In the fourth aspect, the use of long non-coding RNA-lnc-TSI expression promoter or overexpressed long non-coding RNA-lnc-TSI in the preparation of alkaline phosphatase activity inhibitors. Overexpressed long non-coding RNA-lnc-TSI also has an inhibitory effect on the corresponding enzyme in in vitro experiments, and can act directly. For example, inhibiting the expression of alkaline phosphatase ALP. It can also be used for non-diagnostic and therapeutic purposes, generally for in vitro inhibition and regulation. When it is an in vitro inhibitory preparation, the long non-coding RNA-lnc-TSI expression promoter or overexpressed long non-coding RNA-lnc-TSI is used for non-diagnostic and therapeutic purposes in in vitro alkaline phosphatase activity inhibitors.
[0051] The third part further introduces the relevant functions in combination with specific research projects. :
[0052] Experimental methods:
[0053] (I) PCR detection of long noncoding RNAlnc-TSI
[0054] Total RNA extraction (pipette tips and centrifuge tubes are sterilized by wet heat and are RNase-free)
[0055] 1) Use a micropipette to remove the culture medium from the culture flask / plate, add 1 ml of 4°C pre-cooled PBS solution, and shake gently to wash.
[0056] 2) Use a micropipette to remove the PBS.
[0057] 3) Add 1 ml of RNA extraction solution and shake gently or blow with a pipette to break the cells.
[0058] 4) Transfer the liquid into a sterilized 1.5 ml centrifuge tube.
[0059] 5) Add 250 μl of chloroform, invert the centrifuge tube for 15 seconds, mix thoroughly, and let stand for 3 minutes.
[0060] 6) Centrifuge at 12000 rpm for 10 min at 4°C.
[0061] 7) Transfer 400 μl of supernatant to a new centrifuge tube, add 0.8 times the volume of isopropanol, and mix by inversion.
[0062] 8) Place at -20°C for 15 minutes.
[0063] 9) Centrifuge at 12000 rpm for 10 min at 4°C. The white precipitate at the bottom of the tube is RNA.
[0064] 10) Remove the liquid by suction and add 1.5 ml of 75% ethanol to wash the precipitate.
[0065] 11) Centrifuge at 12000 rpm for 10 min at 4°C.
[0066] 12) Aspirate the liquid and place the centrifuge tube on a clean bench to blow for 3 minutes.
[0067] 13) Add 15 μl of RNase-free water to dissolve the RNA.
[0068] 14) Incubate at 55°C for 5 min.
[0069] 15) Use Nanodrop 2000 to detect RNA concentration and purity: After the instrument is blanked and zeroed, take 2.5 μl of the RNA solution to be tested on the detection base, put down the sample arm, and use the software on the computer to start absorbance detection.
[0070] 16) Dilute the RNA with excessive concentration to an appropriate ratio so that the final concentration is 100-500 ng / μl.
[0071] 2. Reverse transcription (the gun tip and PCR are sterilized by wet heat and are free of RNase)
[0072] 1) Take a PCR tube and add a solution containing 2 μg RNA.
[0073] 2) Add 0.5 μl Oligo(dT)18 Primer and 0.5 μl Random Hexamer primer.
[0074] 3) Make up to 15 μl with RNase-free deionized water.
[0075] 4) Incubate at 65°C for 5 min in a PCR instrument and quickly cool on ice.
[0076] 5) Add 4 μl 5× Reaction Buffer, 1 μl RT Enzyme Mix a , mix well by suction with a gun.
[0077] 6) Incubate at 42°C for 60 min in a PCR instrument, then incubate at 70°C for 5 min to inactivate the reverse transcriptase.
[0078] 3. Quantitative PCR
[0079] 1) Take a 0.2 ml PCR tube and prepare the following reaction system, preparing 3 tubes for each reverse transcription product.
[0080] 2×qPCRMix 7.5μl
[0081] 2.5μM gene primer 1.5μl
[0082] Reverse transcription product 2.0 μl
[0083] ddH2O 4.0μl
[0084] 2) PCR amplification
[0085] Pre-denaturation 95℃, 10min
[0086] Cycle (40 times) 95℃, 15s→60℃, 60s
[0087] Melting curve 60℃→95℃, temperature rise 0.3℃ every 15s
[0088] 4. Result processing
[0089] ΔΔCT method:
[0090] A = CT (target gene, sample to be tested) - CT (internal standard gene, sample to be tested)
[0091] B = CT (target gene, control sample) - CT (internal standard gene, control sample)
[0092] K=AB
[0093] Expression multiple = 2 -K
[0094] (II) Bioinformatics analysis of online databases to study the expression of genes related to calcified aortic valves
[0095] Methods: The gene expression profiles of GSE153555 in normal human aortic valve tissue and calcified valve tissue were obtained from the public NCBI-GEO database. RNA sequencing data were based on the GPL16791 platform (Illumina Hiseq 2500 technology), including 10 normal aortic valve tissues, 10 regurgitant aortic valve tissues, and 10 calcified aortic valve tissues. Sequencing data of calcified valves and normal valves were used in the analysis. Fragments per kilobase per million (FPKM) were calculated to estimate gene expression levels. Differential gene expression analysis was performed using the DESeq2R package. A model based on negative binomial distribution was used to determine differential gene expression (log2[fold change]). KEGG pathway enrichment analysis of DEGs was performed, and the Rpackage clusterProfiler was used to annotate genes and analyze the pathways enriched by these genes.
[0096] (III) FISH detection of long noncoding RNAlnc-TSI
[0097] 1. Smear: drop the cell suspension on a poly-lysine treated slide, take another slide as a push slide, move the push slide from the left side of the cell drop to the right, when the cell drop is evenly attached between the two slides, move the push slide steadily to the left (the two slides form an angle of 30 to 40 degrees) to push out a uniform cell membrane, and bake it over an alcohol lamp several times to dry it.
[0098] 2. Place the dried cell smear in a 10 cm dish, add 100 μl 0.1% Buffer A (prepared immediately before use) and treat the cells at room temperature for 15 minutes.
[0099] 3. Aspirate and discard 0.1% Buffer A, and add PBS to wash twice, 5 minutes each time.
[0100] 4. Aspirate and discard PBS, add 100 μl 2×Buffer C, and place in a 37°C incubator for 30 min.
[0101] 5. Incubate Buffer E in a 73℃ water bath for 30 min until it becomes clear and translucent.
[0102] 6. Probe dilution: Refer to the parameters shown on the label or report: nmole / OD260. For example, if nmole / OD260=4.17, add 41.7μl sterilized DEPC water to each OD probe dry powder product. Mix well to obtain a storage solution with a concentration of about 100μM. It is recommended to store it at -20℃ in the dark after aliquoting to avoid multiple freeze-thaw operations.
[0103] 7. Prepare probe mixture: Take 100μl probe mixture as an example, that is, probe Xμl (you can do a preliminary experiment to determine the required probe concentration: it is recommended that you set different working concentration gradients for preliminary experiments, for example: 0.5μM, 1μM, 2μM, 4μM, 8μM) add Buffer E, the total system is 100μl, and denature at 73℃ for 5min.
[0104] 8. Prepare a wet box, place the slices horizontally, add 10 μl of denatured probe mixture to each slice, cover with a coverslip, and seal with sealing glue.
[0105] 9. Place in an in situ hybridization apparatus and incubate at 37°C for 12-16 hours (if there is no hybridization apparatus, add 100 μl of denatured probe mixture and incubate directly in a 37°C incubator for 12-16 hours).
[0106] 10. On the second day of hybridization, take the samples out of the 37°C incubator, gently remove the coverslip, aspirate and discard the probe mixture, add 100 μl of 0.1% Buffer F preheated at 42°C to each slide and wash for 5 minutes.
[0107] 11. Aspirate and discard 0.1% Buffer F, add 100 μl of 2× Buffer C preheated at 42°C to each slide and wash for 5 minutes.
[0108] 12. Aspirate and discard 2× Buffer C, add 100 μl of 1× Buffer C preheated at 42°C to each slide and wash for 5 min. Aspirate and discard the washing solution and dry at room temperature.
[0109] 13. Add 100 μl of diluted DAPI working solution to each slide and stain for 20 minutes in the dark.
[0110] 14. Aspirate and discard the DAPI working solution, add 100 μl PBS to each slide and wash twice, 2 minutes each time; 15. Add glycerol or anti-fading agent, cover with a coverslip, seal the slide with sealing glue and observe under a fluorescence microscope
[0111] (IV) Extraction and culture of primary human valvular interstitial cells
[0112] 1. Collect the normal aortic valves in the first part and put them into a 15ml centrifuge tube, transfer them to the clean bench in a 4℃ ice box, pour out the culture medium, transfer the valves into a sterile six-well plate, and rinse them repeatedly with sterile PBS containing double antibodies for 6 times.
[0113] 2. Carefully transfer the valve into a 15 ml sterile centrifuge tube, add 10 ml of (2 mg / ml) type I collagenase solution, and place in a 37°C, 5% CO2 incubator for 10 hours, shaking every 2 hours until the valve tissue is decomposed into flocs and dispersed completely.
[0114] Centrifuge at 3.500g for 5 minutes, discard the supernatant, and the precipitate at the bottom is the digested primary cells.
[0115] 4. Add 4 ml of culture medium solution containing 10% FBS, mix thoroughly, add the cell suspension into a sterile culture bottle, shake gently to spread it evenly, and place it in a 37°C, 5% CO2 incubator.
[0116] 5. After 2-3 days, observe that the cells have attached to the wall and replace the culture medium. When the cell proliferation growth reaches 80-90% of the culture flask area, subculture again.
[0117] 6. Subculturing: discard the culture medium, add 1 ml of trypsin to the culture bottle and digest for 30 seconds under a microscope, discard the trypsin, add 6 ml of complete culture medium. Use a sterile pipette to blow the bottom of the culture bottle to make the adherent cells fall off into a uniform cell suspension and transfer it to two culture bottles. Transfer to the incubator for further culture at a ratio of 3 ml of solution per T25 culture bottle.
[0118] 7. The ability of primary cells to divide and proliferate is limited. It usually takes about 5-7 days from inoculation to the next subculture, and the subculture ratio is 1:2. After the 6th-7th generation, the cells stop dividing and proliferating, and the cell activity deteriorates, which cannot meet the experimental requirements. Therefore, 3-5th generation cells are selected for relevant experimental tests.
[0119] Alizarin red staining
[0120] 1. Select valvular interstitial cells of passage 3-5, culture and digest the cells according to the above method, inoculate them into 12-well plates, add 1 ml of complete culture medium to each well, and culture them in an incubator for 48 hours.
[0121] 2. When the cells are completely attached and grow to about 80-90%, replace the complete culture medium with a culture medium containing 2% FBS and continue culturing for 8 hours to adjust the cell cycle, stop the cells from dividing and proliferating, and maintain them in a dormant phase to facilitate better acceptance of subsequent interventions.
[0122] 3. Add TGF-β (10 ng / ml) to the culture medium containing 2% FBS, replace the culture medium with fresh one every three days, and continue culturing for 3 weeks.
[0123] 5. Remove the culture medium from the 12-well plate, wash with PBS 5 times, add 1 ml of 4% paraformaldehyde solution, and fix for 10 minutes.
[0124] 6. Remove the 4% neutral paraformaldehyde solution, wash with double distilled water 5 times, add 800ul of Alizarin Red dye solution, and incubate at room temperature for 30 minutes.
[0125] 7. Use a pipette to remove the Alizarin Red dye solution, add 2 ml of double distilled water, wash 5 times on a shaker at room temperature, 3 minutes each time, and collect images.
[0126] Small interfering RNA (siRNA) transfection into human valvular interstitial cells
[0127] 1. After the valvular interstitial cells are seeded in a six-well plate, they are used for transfection when they grow to about 70-80%.
[0128] 2. Prepare lipo3000 dilution solution, add 150ul Opti-MEM + 150ul culture medium into EP tube, add 7ul Lipo3000 and 7ul siRNA scramble or target gene siRNA, gently blow 5 times with the pipette tip to obtain 300ul transfection complex in each well, mix it thoroughly, and let it stand at room temperature for 15 minutes.
[0129] 3. Aspirate the complete medium, add 1.7 ml of fresh complete medium, then add the corresponding transfection complex, and shake to mix.
[0130] 4. In a 37°C CO2 incubator, replace the complete culture medium after 8 hours of culture. After 48 hours, protein extraction or cell intervention can be performed. The optimal siRNA transfection concentration can be selected based on the WB results.
[0131] Western blot (WB)
[0132] 1. Extraction of proteins from human aortic valve tissue
[0133] 1. Take out the cryotube containing the valve tissue specimen from the liquid nitrogen tank, insert dry ice, and after the liquid nitrogen in the cryotube evaporates completely, take out the valve tissue and weigh and record it.
[0134] 2. After cleaning the ceramic pestle and mortar, pour in 75% alcohol and ignite to remove possible interference from contaminating proteins. After the pestle and mortar cool to room temperature, put in the aortic valve tissue and pour in liquid nitrogen for grinding until the tissue is ground into powder.
[0135] 3. Transfer the powder to a 1.5 mL clean EP tube and add RIPA lysis buffer containing 1:100 protease inhibitors at a ratio of 150 uL lysis buffer per 30 mg tissue.
[0136] 4. Insert the ultrasonic cell disruptor probe into the EP tube, and perform ultrasonic disruption on ice for 20 seconds, 25 seconds between each disruption, for a total of 3 times. Then centrifuge at 12000rpm, 4℃ for 15 minutes, and extract the supernatant as tissue protein solution. It can be stored in a -80℃ refrigerator or proceed directly to the next step.
[0137] (II) Protein concentration determination (BCA method)
[0138] 1. Dilute the standard protein (BSA) according to the instructions of the BCA kit of Biyuntian: add 10 mg BSA to 400 uL PBS to obtain 25 mg / mL BSA protein solution.
[0139] 2. Dilute the BSA protein solution with PBS to a 0.5 mg / mL protein standard solution.
[0140] 3. Add 0, 1, 2, 4, 8, 12, 16, and 20 ul of standard protein to the 96-well plate, and then fill each well with the corresponding volume of PBS to 20 ul (e.g. Figure 5 ).
[0141] 4. Add 19ul of PBS and 1ul of protein sample to the wells to be tested.
[0142] 5. Prepare BCA working solution at a ratio of A solution: B solution = 50:1, add 200ul of BCA working solution to each well, and place at 37℃ for 30min.
[0143] 6. Under the condition of 562nm wavelength of the microplate reader, measure the absorbance of the sample and the protein sample to be tested, establish a standard curve, and calculate the concentration of the protein sample to be tested.
[0144] (III) Protein denaturation
[0145] 1. Add 5x SDS loading buffer to the protein sample obtained above and mix thoroughly.
[0146] 2. Place the 1.5ml EP tube containing the protein sample on a 95℃ heater for 10 minutes to allow it to be completely denatured. After cooling on ice, it can be used for electrophoresis experiments.
[0147] A two-step PCR reaction procedure was used to calculate the CT value, and GAPDH was used as an internal reference to calculate the 2-△△Ct value. The primers were designed as follows:
[0148] Homolnc-TSI-F AATCTGGTGTGGACAAACGC Homolnc-TSI-R AACAGATGCTTCCGAATGCC
[0149] Sequences(5′-3′)ofsiRNA for Smad2,Smad3 and lnc-TSI
[0150] Homosi-lnc-TSI-1 GGAAUCUGGUGUGGACAAATT Homosi-lnc-TSI-2 CUGAGAGCCAUGGAUUUAATT
[0151] Probes used in FISH / FISH assays
[0152] Gene Sequence lnc-TSI ACATCTCTTAATCAGCGAATCA
[0153] Sequence oflnc-TSI(SEQ ID NO:1):
[0154] GGCTTCCCTGCTCAGAGGCAGGGAATTGTGCAGCTGGAGTTTCATTTTCCAAGCTGCAGCTGTGGGTGATTCGGATGGTCTGTTGGTGGAATGTGGAGCTGGACGGGTCAAGGAGCACAGTGTGGAAAGAGGGACAATTTGCTACAAGTTGGAGATAAGAGACATGGCATACTGTGAAACCAGTGCTGACGGAAGAAGGTGACTTTCTTGGAAGGTCAAGACACTTGCTTGACAGCGATGTCCAGGAGGGCTAGGGAGAGTTCTGCTGGAAGTGAAGGCAGCACCTGAGGGTGGCTGAGGGAACTGGTCAGGGCTGGGAACGCCTCCAGCCCTTTGAGGAATGATTCGCTGATTAAGAGATGTTTGGCCTTGAAAATTGCAAGAATGAAATCTCTTGGTGGGAATGTGTAGCCAAAAGCCAGCACCCTGAGTGGCTCCAAGGTTTGGGGACCCTCTCAAGGCACAAATCCCAGTTCCTTTTCAATTTTGAAAATCGTTGTGGGCGATTCTGGAATTGAGAAGTGTGCTGAGAGCCATGGATTTAACATGACAAGAATTTCCGCCCCTTCGTCACTGAGCACACCGCAAATGCTCCAGGGCCAGGGACTTACTTGGGCTTCTGCGTGTCTTCCACAGTGTGCATCAATCCGCCGGGCTCTGGTTGGTGTTTAAAAAAAAAGATGCAGCGAAGGAATCTGGTGTGGACAAACGCCCTGGGCATGGACCAAAAGCCTGGCCCTTGTGTCCCTGGCAATGGGACGGTGAAGGACAGAAAGACAGCACATCCAGTAGTGTCAGGAGCTTGGAGCAGGCATTCGGAAGCATCTGTTAAATGTTATTGATGGAGGATTGACATAACCCACATCTGCATAGCTTTTTTGGTCTGTTTTTGGAAGTGAACAGTCACAAACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA。
[0155] Experimental results
[0156] (1) The present invention detected the increased expression of TGF-β1, runx2, college I, and SAMD3 in human aortic valve tissue and found that the expression of long noncoding RNA lnc-TSI was increased, suggesting that long noncoding RNAlnc-TSI can be used as a diagnostic marker for calcific aortic valve disease.
[0157] (2) At the same time, by detecting the effect of Long noncoding RNA lnc-TSI on the osteogenic differentiation of aortic valve interstitial cells, it was found that overexpression of Long noncoding RNA lnc-TSI significantly reduced the osteogenic differentiation of human aortic valve interstitial cells, providing a method for treating aortic valve calcification by inhibiting the osteogenic differentiation of human aortic valve interstitial cells. This provides a new idea for anti-aortic valve calcification treatment targeting Long noncoding RNA lnc-TSI.
[0158] I). The expression of TGF-β1, Runx2, collage I, and SAMD3 increased in calcified valves.
[0159] Bioinformatics analysis revealed that Figure 1 Figure AB shows that genes such as TGF-β1, Runx2, and collageI are highly expressed in calcified valves.
[0160] The calcium salts deposited in the calcified aortic valve are mainly hydroxyphosphates. The dye alizarin red can combine with the calcium ions in a chelating manner to form a complex, forming calcium nodule staining. Therefore, in addition to B-ultrasound and naked eye observation to determine aortic valve calcification, alizarin red staining can also be performed for verification. The collected valve tissues were subjected to alizarin red staining, immunohistochemistry, and WB testing. The results of alizarin red and immunohistochemistry showed that, if Figure 1 Middle C shows: normal valves have no alizarin red dye attached, no calcification, and low expression of TGF-β1, Runx2, and collage I; calcified valves have alizarin red dye attached, and high expression of TGF-β1, Runx2, and collage I. WB detection, such as Figure 1 Middle DG shows that Runx2 and collage I were upregulated in calcified valve tissues, and there was a statistical difference. Figure 1 H shows that TGF-β1 is upregulated in calcified valve tissue.
[0161] like Figure 1As shown in. Bioinformatics analysis. A: Heat map of TGF-β1, Runx2, and collage I related gene expression; B: Volcano map of TGF-β1, Runx2, and collage I related gene differences; C: No alizarin red dye was attached to the normal valve, no calcification, and Runx2 and collage I were highly expressed around the calcified tissue; DG: WB representative images and quantitative statistical graphs of Runx2, ALP, and TGF-β1 expression in valve tissues of the control group and calcification group; H: Expression of TGF-β1 immunofluorescence in calcified valves. (* indicates P < 0.05 vs Normal, ** indicates P < 0.01 vs Normal, *** indicates P < 0.001 vs Normal, n = 10).
[0162] II). TGF-β1 can promote the high expression of RUNx2 and collageI in VICs.
[0163] In order to screen out the optimal intervention concentration and time of TGF-β1 on VICs, a concentration and time gradient was designed to detect the effect of TGF-β1 on the osteogenic differentiation of VICs. 0ng / ml, 1ng / ml, 5ng / ml, 10ng / ml, and 20ng / ml OSM were used to intervene in VICs for 48h, and the expression of osteogenic differentiation-related proteins was detected by WB. Figure 2 AC shows that TGF-β1 up-regulated the expression of osteogenic differentiation-related proteins Runx2 and collage I in VICs in a concentration-dependent manner. 10 ng / ml TGF-β1 was used to intervene in VICs for 0 h, 12 h, 24 h, 48 h, and 72 h. Figure 2 Middle DF shows that the expression of osteogenic differentiation-related proteins Runx2 and ALP was upregulated at 24h, 48h and 72h, and there was a statistical difference. Therefore, 10ng / ml TGF-β1 intervention in VICs for 48h can cause the upregulation of osteogenic differentiation-related proteins, and this intervention condition was used in subsequent experiments.
[0164] Figure 2 :TGF-β1 promotes high expression of Runx2 and Collage I in VICs. A: Different concentrations of TGF-β1 intervened in VICs for 48h, Runx2 and Collage I protein expression band diagram; BC: Runx2 and Collage I expression statistics in A; D: Runx2 and Collage I protein expression band diagram after 10ng / ml TGF-β1 intervened in VICs for different time periods; EF: Runx2 and ALP expression statistics in D. (* indicates P<0.05, ** indicates P<0.01vs, *** indicates P<0.001, n=3).
[0165] III).VICs activation is accompanied by high expression of lnc-TSI.
[0166] like Figure 3 Information shown in. A: After 48 hours of intervention in VICs, PCR detection revealed that lnc-TSI expression increased, B: Fish in situ hybridization detection revealed that lnc-TSI expression increased and was positively correlated with the degree of VICs activation.
[0167] The detection agent in Fish in situ hybridization detection can use long non-coding RNA-lnc-TSI detection agent.
[0168] IV). Overexpression of lnc-TSI can reduce osteoblastic differentiation, and knockdown of lnc-TSI can increase osteoblastic differentiation of VICs.
[0169] Overexpression of lnc-TSI was used to act on TGF-β1 to pretreat VICs, and WB was used to detect the expression levels of RUNx2 and collageI. Figure 4 AC shows that after overexpression of lnc-TSI, the expression levels of RUNx2, collageI, and ALP were significantly reduced. Figure 4 Figures DF in the middle show that after knocking down lnc-TSI, the expression levels of RUNx2 and collageI increased significantly. Figure 4 Figure GH shows that 10ng / ml TGF-β1 intervened VICs for 14 days. Figure 4 Middle H shows: Compared with the control group, the formation of VICs calcium nodules in the TGF-β1 group increased and was statistically significant. After overexpression of lnc-TSI, the formation of VICs calcium nodules decreased. After knocking down lnc-TSI, the formation of VICs calcium nodules increased and was statistically significant.
[0170] Many long noncoding RNAs have been shown to regulate osteogenic differentiation of human valvular interstitial cells, such as LncRNAOIP5-AS1, LncRNA OIP5-AS1, LncRNAMALAT1, etc. In the related research of this project, through bioinformatics analysis, it was found that the expression of TGF-β1, runx2, college I, and SAMD3 in calcified valves increased. By stimulating VICs, it was found that the expression of Longnoncoding RNA lnc-TSI increased accordingly. It was verified that overexpression of Long noncoding RNAlnc-TSI can reduce osteogenic differentiation of valvular interstitial cells. It also showed the inhibitory effect on the corresponding proteins or enzymes.
[0171] It will be clear to those skilled in the art that various modifications to the above embodiments may be made without departing from the overall spirit and concept of the present invention. All of them fall within the protection scope of the present invention. The protection scheme of the present invention shall be subject to the claims attached to the present invention.
Claims
1. Application of reagents for detecting the expression of long non-coding RNA-lnc-TSI in the preparation of products for diagnosing calcific aortic valve disease; wherein, The long non-coding RNA-lnc-TSI sequence is shown as SEQ ID NO:
1.
2. The use according to claim 1, characterized in that: The reagent for detecting the expression of long non-coding RNA-lnc-TSI is at least a detection primer and / or a detection probe; the product for diagnosing calcific aortic valve disease is at least a kit containing a detection primer and / or a detection probe.
3. The use according to claim 2, characterized in that: The detection primer pairs are: F: 5'-AATCTGGTGTGGACAAACGC-3', R: 5'-AACAGATGCTTCCGAATGCC-3'; The detection probe is: 5'-ACATCTCTTAATCAGCGAATCA-3'.
4. The use according to claim 1, characterized in that: Overexpression of long noncoding RNA-lnc-TSI reduced the differentiation level of aortic valve interstitial cells.
5. Application of reagents for detecting the expression of long non-coding RNA-lnc-TSI in the preparation of products for detecting the differentiation level of aortic valve interstitial cells; wherein, The long non-coding RNA-lnc-TSI sequence is shown as SEQ ID NO:
1.
6. The use according to claim 5, characterized in that: The reagent for detecting the expression of long non-coding RNA-lnc-TSI is at least a detection primer and / or a detection probe; the product for detecting the differentiation level of aortic valve interstitial cells is at least a kit containing a detection primer and / or a detection probe.
7. The use according to claim 6, characterized in that: The detection primer pairs are: F: 5'-AATCTGGTGTGGACAAACGC-3', R: 5'-AACAGATGCTTCCGAATGCC-3'; The detection probe is: 5'-ACATCTCTTAATCAGCGAATCA-3'.
